{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:17:05Z","timestamp":1783574225505,"version":"3.55.0"},"reference-count":75,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health &amp; Welfare, Republic of Korea","award":["RS-2024-00512498"],"award-info":[{"award-number":["RS-2024-00512498"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Glioblastoma remains the most aggressive primary brain malignancy, with poor survival despite maximal safe resection, radiotherapy, and temozolomide-based chemotherapy. A major obstacle to effective treatment is the spatially heterogeneous blood\u2013brain barrier\/blood\u2013tumor barrier, which restricts drug penetration into infiltrative tumor regions and limits uniform intratumoral exposure. Albumin-based delivery is attractive in glioblastoma because it addresses several formulation-level barriers at once: poor aqueous solubility of hydrophobic payloads, short systemic exposure, and the need for a biocompatible carrier that can interact with albumin-handling pathways such as gp60\/albondin, SPARC, FcRn, and caveolin-associated transport. This review examines albumin-based strategies explored for glioblastoma, with an emphasis on albumin-bound paclitaxel nanoparticles, engineered albumin nanoparticles, dual-payload systems, albumin-binding photosensitizers, macrophage-assisted delivery, and albumin-bound pathway-directed agents. Preclinical evidence suggests that these platforms can improve brain-tumor drug exposure, support rational combinations, and synergize with BBB\/BTB-opening technologies. Early clinical studies combining low-intensity pulsed ultrasound with microbubbles and albumin-bound paclitaxel provide human proof of concept for regional pharmacokinetic enhancement in recurrent glioblastoma, although survival benefit remains unproven. The available evidence supports albumin-based delivery as a rational formulation strategy. Its clinical value in GBM will depend on three testable requirements: spatial pharmacokinetic confirmation, biomarker-guided patient selection, and reproducible BBB\/BTB modulation.<\/jats:p>","DOI":"10.3390\/cells15131180","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T15:27:37Z","timestamp":1782746857000},"page":"1180","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Albumin-Based Drug Delivery for Glioblastoma Treatment: Mechanistic Rationale, Preclinical Evidence, and Clinical Translation"],"prefix":"10.3390","volume":"15","author":[{"given":"Myung Geun","family":"Song","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul 03080, Republic of Korea"},{"name":"Biomedical Research Institute, Seoul National University Hospital, Seoul 03080, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2622-9017","authenticated-orcid":false,"given":"Keon Wook","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul 03080, Republic of Korea"},{"name":"Biomedical Research Institute, Seoul National University Hospital, Seoul 03080, Republic of Korea"},{"name":"Department of Biomedical Sciences, Seoul National University Graduate School, Seoul 03080, Republic of Korea"},{"name":"Cancer Research Institute, Seoul National University College of Medicine, Seoul 03080, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: A Summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro-Oncology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/neuonc\/noaa106","article-title":"Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions","volume":"22","author":"Wen","year":"2020","journal-title":"Neuro-Oncology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/noaf194","article-title":"CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2018\u20132022","volume":"27","author":"Price","year":"2025","journal-title":"Neuro-Oncology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41573-021-00139-y","article-title":"Strategies for Delivering Therapeutics across the Blood\u2013Brain Barrier","volume":"20","author":"Terstappen","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5909","DOI":"10.1038\/s41467-023-41694-9","article-title":"Breaking Barriers for Glioblastoma with a Path to Enhanced Drug Delivery","volume":"14","author":"Noorani","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/neuonc\/nox175","article-title":"Is the Blood-Brain Barrier Really Disrupted in All Glioblastomas? A Critical Assessment of Existing Clinical Data","volume":"20","author":"Sarkaria","year":"2018","journal-title":"Neuro-Oncology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jconrel.2011.07.031","article-title":"Albumin-Based Nanoparticles as Potential Controlled Release Drug Delivery Systems","volume":"157","author":"Elzoghby","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jconrel.2008.05.010","article-title":"Albumin as a Drug Carrier: Design of Prodrugs, Drug Conjugates and Nanoparticles","volume":"132","author":"Kratz","year":"2008","journal-title":"J. Control. Release"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jconrel.2025.01.035","article-title":"Albumin-Based Delivery Systems: Recent Advances, Challenges, and Opportunities","volume":"380","author":"Murphy","year":"2025","journal-title":"J. Control. Release"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Sand, K.M.K., Bern, M., Nilsen, J., Noordzij, H.T., Sandlie, I., and Andersen, J.T. (2015). Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics. Front. Immunol., 5.","DOI":"10.3389\/fimmu.2014.00682"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Ji, Q., Zhu, H., Qin, Y., Zhang, R., Wang, L., Zhang, E., Zhou, X., and Meng, R. (2024). GP60 and SPARC as Albumin Receptors: Key Targeted Sites for the Delivery of Antitumor Drugs. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1329636"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1038\/s41565-024-01754-7","article-title":"A Translational Framework to DELIVER Nanomedicines to the Clinic","volume":"19","author":"Joyce","year":"2024","journal-title":"Nat. Nanotechnol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S1470-2045(23)00112-2","article-title":"Repeated Blood\u2013Brain Barrier Opening with an Implantable Ultrasound Device for Delivery of Albumin-Bound Paclitaxel in Patients with Recurrent Glioblastoma: A Phase 1 Trial","volume":"24","author":"Sonabend","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jmb.2005.07.075","article-title":"Structural Basis of the Drug-Binding Specificity of Human Serum Albumin","volume":"353","author":"Ghuman","year":"2005","journal-title":"J. Mol. Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"13492","DOI":"10.1074\/jbc.M114.549832","article-title":"Extending Serum Half-Life of Albumin by Engineering Neonatal Fc Receptor (FcRn) Binding*","volume":"289","author":"Andersen","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1084\/jem.20021829","article-title":"The Major Histocompatibility Complex\u2013Related Fc Receptor for IgG (FcRn) Binds Albumin and Prolongs Its Lifespan","volume":"197","author":"Chaudhury","year":"2003","journal-title":"J. Exp. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jconrel.2007.02.010","article-title":"Anti-PEG IgM Elicited by Injection of Liposomes Is Involved in the Enhanced Blood Clearance of a Subsequent Dose of PEGylated Liposomes","volume":"119","author":"Wang","year":"2007","journal-title":"J. Control. Release"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"25968","DOI":"10.1074\/jbc.272.41.25968","article-title":"Gp60 Activation Mediates Albumin Transcytosis in Endothelial Cells by Tyrosine Kinase-Dependent Pathway*","volume":"272","author":"Tiruppathi","year":"1997","journal-title":"J. Biol. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1083\/jcb.150.5.1057","article-title":"Endothelial Cell-Surface Gp60 Activates Vesicle Formation and Trafficking via Gi-Coupled Src Kinase Signaling Pathway","volume":"150","author":"Minshall","year":"2000","journal-title":"J. Cell Biol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"9999","DOI":"10.1021\/acsnano.6b04268","article-title":"Blood\u2013Brain-Barrier-Penetrating Albumin Nanoparticles for Biomimetic Drug Delivery via Albumin-Binding Protein Pathways for Antiglioma Therapy","volume":"10","author":"Lin","year":"2016","journal-title":"ACS Nano"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1158\/1078-0432.CCR-05-1634","article-title":"Increased Antitumor Activity, Intratumor Paclitaxel Concentrations, and Endothelial Cell Transport of Cremophor-Free, Albumin-Bound Paclitaxel, ABI-007, Compared with Cremophor-Based Paclitaxel","volume":"12","author":"Desai","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40824-023-00360-3","article-title":"Albumin-Binding Photosensitizer Capable of Targeting Glioma via the SPARC Pathway","volume":"27","author":"Li","year":"2023","journal-title":"Biomater. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4811","DOI":"10.1158\/1078-0432.CCR-14-3222","article-title":"SPARC Expression Did Not Predict Efficacy of Nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial","volume":"21","author":"Hidalgo","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jconrel.2016.11.015","article-title":"To Exploit the Tumor Microenvironment: Since the EPR Effect Fails in the Clinic, What Is the Future of Nanomedicine?","volume":"244","author":"Danhier","year":"2016","journal-title":"J. Control. Release"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1152\/physrev.00001.2003","article-title":"Transcytosis: Crossing Cellular Barriers","volume":"83","author":"Tuma","year":"2003","journal-title":"Physiol. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering Precision Nanoparticles for Drug Delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1158\/2326-6066.CIR-16-0125","article-title":"Macropinocytosis of Nab-Paclitaxel Drives Macrophage Activation in Pancreatic Cancer","volume":"5","author":"Cullis","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Xie, Z., Ye, J., Gao, X., Chen, H., Chen, M., Lian, J., Ma, J., and Wang, H. (2024). Evaluation of Nanoparticle Albumin-Bound Paclitaxel Loaded Macrophages for Glioblastoma Treatment Based on a Microfluidic Chip. Front. Bioeng. Biotechnol., 12.","DOI":"10.3389\/fbioe.2024.1361682"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s43018-025-01097-9","article-title":"Immunosuppressive Mechanisms and Therapeutic Interventions Shaping Glioblastoma Immunity","volume":"7","author":"Rezaeipour","year":"2026","journal-title":"Nat. Cancer"},{"key":"ref_31","first-page":"1038","article-title":"Phase I and Pharmacokinetic Study of ABI-007, a Cremophor-Free, Protein-Stabilized, Nanoparticle Formulation of Paclitaxel","volume":"8","author":"Ibrahim","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0959-8049(01)00171-X","article-title":"Cremophor EL: The Drawbacks and Advantages of Vehicle Selection for Drug Formulation","volume":"37","author":"Gelderblom","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","article-title":"Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil\u2013Based Paclitaxel in Women With Breast Cancer","volume":"23","author":"Gradishar","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1158\/1078-0432.CCR-19-2182","article-title":"Ultrasound-Mediated Delivery of Paclitaxel for Glioma: A Comparative Study of Distribution, Toxicity, and Efficacy of Albumin-Bound Versus Cremophor Formulations","volume":"26","author":"Zhang","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.2147\/IJN.S450853","article-title":"Nanoparticle-Based Combinational Strategies for Overcoming the Blood-Brain Barrier and Blood-Tumor Barrier","volume":"19","author":"Lim","year":"2024","journal-title":"Int. J. Nanomed."},{"key":"ref_36","first-page":"930","article-title":"Albumin-Based Nanoparticles: A Promising Strategy to Overcome Cancer Drug Resistance","volume":"3","author":"Hassanin","year":"2020","journal-title":"Cancer Drug Resist."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s12079-009-0072-4","article-title":"SPARC: A Matricellular Regulator of Tumorigenesis","volume":"3","author":"Arnold","year":"2009","journal-title":"J. Cell Commun. Signal."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s12079-009-0062-6","article-title":"The Role of SPARC in Extracellular Matrix Assembly","volume":"3","author":"Bradshaw","year":"2009","journal-title":"J. Cell Commun. Signal."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/s41588-025-02168-4","article-title":"Deciphering the Longitudinal Trajectories of Glioblastoma Ecosystems by Integrative Single-Cell Genomics","volume":"57","author":"Spitzer","year":"2025","journal-title":"Nat. Genet."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrc1317","article-title":"Microtubules as a Target for Anticancer Drugs","volume":"4","author":"Jordan","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"5891","DOI":"10.1158\/0008-5472.CAN-17-3480","article-title":"Paclitaxel Reduces Tumor Growth by Reprogramming Tumor-Associated Macrophages to an M1 Profile in a TLR4-Dependent Manner","volume":"78","author":"Wanderley","year":"2018","journal-title":"Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.7150\/thno.92672","article-title":"IL4 Receptor Targeting Enables Nab-Paclitaxel to Enhance Reprogramming of M2-Type Macrophages into M1-like Phenotype via ROS-HMGB1-TLR4 Axis and Inhibition of Tumor Growth and Metastasis","volume":"14","author":"Vadevoo","year":"2024","journal-title":"Theranostics"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1038\/s41467-023-40579-1","article-title":"Optical Blood-Brain-Tumor Barrier Modulation Expands Therapeutic Options for Glioblastoma Treatment","volume":"14","author":"Cai","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"137","DOI":"10.15252\/emmm.201606857","article-title":"Genetically Engineered Mouse Models in Oncology Research and Cancer Medicine","volume":"9","author":"Kersten","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"ref_45","first-page":"285","article-title":"Albumin-Bound Paclitaxel Augment Temozolomide Treatment Sensitivity of Glioblastoma Cells by Disrupting DNA Damage Repair and Promoting Ferroptosis","volume":"42","author":"Qu","year":"2023","journal-title":"J. Exp. Clin. Cancer Res. CR"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jconrel.2019.07.015","article-title":"Codelivery of Paclitaxel and Temozolomide through a Photopolymerizable Hydrogel Prevents Glioblastoma Recurrence after Surgical Resection","volume":"309","author":"Zhao","year":"2019","journal-title":"J. Control. Release"},{"key":"ref_47","unstructured":"ClinicalTrials.gov (2026, June 12). A Controlled, Randomized, Phase III, Multicenter, Open Label Study of ABI-007 (a Cremophor Free, Protein Stabilized, Nanoparticle Paclitaxel) and Taxol in Patients with Metastatic Breast Cancer. NCT00046527, Available online: https:\/\/clinicaltrials.gov\/study\/NCT00046527."},{"key":"ref_48","unstructured":"ClinicalTrials.gov (2026, June 12). A Randomized, Phase III Trial of ABI-007 and Carboplatin Compared with Taxol and Carboplatin as First-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC). NCT00540514, Available online: https:\/\/clinicaltrials.gov\/study\/NCT00540514."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1200\/JCO.2011.39.5848","article-title":"Weekly Nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non\u2013Small-Cell Lung Cancer: Final Results of a Phase III Trial","volume":"30","author":"Socinski","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_50","unstructured":"ClinicalTrials.gov (2026, June 12). A Randomized Phase III Study of Weekly ABI-007 Plus Gemcitabine Versus Gemcitabine Alone in Patients with Metastatic Adenocarcinoma of the Pancreas. NCT00844649, Available online: https:\/\/clinicaltrials.gov\/study\/NCT00844649."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased Survival in Pancreatic Cancer with Nab-Paclitaxel plus Gemcitabine","volume":"369","author":"Ervin","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_52","unstructured":"ClinicalTrials.gov (2026, June 12). Phase 1\/2 Trial of Blood-Brain Barrier Opening with an Implantable Ultrasound Device SonoCloud-9 and Treatment With Albumin-Bound Paclitaxel and Carboplatin in Patients with Recurrent Glioblastoma. NCT04528680, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04528680."},{"key":"ref_53","unstructured":"ClinicalTrials.gov (2026, June 12). A Phase 2, Open-Label Study of ABI-009 (Nab-Rapamycin) in Patients with Recurrent High-Grade Glioma and Patients with Newly Diagnosed Glioblastoma. NCT03463265, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03463265."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e70376","DOI":"10.1002\/cam4.70376","article-title":"A Phase 1 Study of ABI-009 (Nab-Sirolimus) in Combination With Temozolomide and Irinotecan in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors\u2014A Children\u2019s Oncology Group Pediatric Early Phase Clinical Trial Network Study ADVL1514","volume":"13","author":"Cramer","year":"2024","journal-title":"Cancer Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"vdae186","DOI":"10.1093\/noajnl\/vdae186","article-title":"Phase II Trial of Blood\u2013Brain Barrier Permeable Peptide-Paclitaxel Conjugate ANG1005 in Patients with Recurrent High-Grade Glioma","volume":"6","author":"Dmello","year":"2024","journal-title":"Neuro-Oncol. Adv."},{"key":"ref_56","first-page":"e12407","article-title":"Incidence and Risk of Peripheral Neuropathy with Nab-Paclitaxel in Patients with Cancer: A Meta-Analysis","volume":"26","author":"Peng","year":"2017","journal-title":"Eur. J. Cancer Care"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.critrevonc.2019.04.021","article-title":"Does Nab-Paclitaxel Have a Higher Incidence of Peripheral Neuropathy than Solvent-Based Paclitaxel? Evidence from a Systematic Review and Meta-Analysis","volume":"139","author":"Guo","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00280-020-04140-x","article-title":"Pharmacokinetic and Pharmacodynamic Analysis of Neutropenia Following Nab-Paclitaxel Administration in Japanese Patients with Metastatic Solid Cancer","volume":"86","author":"Tsushima","year":"2020","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1038\/ncomms5196","article-title":"Disruption of Astrocyte\u2013Vascular Coupling and the Blood\u2013Brain Barrier by Invading Glioma Cells","volume":"5","author":"Watkins","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.1158\/1078-0432.CCR-21-2563","article-title":"Translocon-Associated Protein Subunit SSR3 Determines and Predicts Susceptibility to Paclitaxel in Breast Cancer and Glioblastoma","volume":"28","author":"Dmello","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"106687","DOI":"10.1016\/j.isci.2023.106687","article-title":"A Novel IRE1 Kinase Inhibitor for Adjuvant Glioblastoma Treatment","volume":"26","author":"Doultsinos","year":"2023","journal-title":"iScience"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41586-025-08997-x","article-title":"Glioblastoma-Instructed Astrocytes Suppress Tumour-Specific T Cell Immunity","volume":"643","author":"Andersen","year":"2025","journal-title":"Nature"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41556-025-01839-y","article-title":"Inhibiting Macrophage-Derived Lactate Transport Restores cGAS\u2013STING Signalling and Enhances Antitumour Immunity in Glioblastoma","volume":"28","author":"Li","year":"2026","journal-title":"Nat. Cell Biol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"115702","DOI":"10.1016\/j.addr.2025.115702","article-title":"In Vitro Models of the Interplay between Glioblastoma and Blood\u2013Brain Barrier for Stratifying Drug Efficacy","volume":"227","author":"Ferreira","year":"2025","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.cell.2019.11.036","article-title":"A Patient-Derived Glioblastoma Organoid Model and Biobank Recapitulates Inter- and Intra-Tumoral Heterogeneity","volume":"180","author":"Jacob","year":"2020","journal-title":"Cell"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.stem.2024.11.010","article-title":"Patient-Derived Glioblastoma Organoids as Real-Time Avatars for Assessing Responses to Clinical CAR-T Cell Therapy","volume":"32","author":"Logun","year":"2025","journal-title":"Cell Stem Cell"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/S1470-2045(25)00492-9","article-title":"Microbubble-Enhanced Transcranial Focused Ultrasound with Temozolomide for Patients with High-Grade Glioma (BT008NA): A Multicentre, Open-Label, Phase 1\/2 Trial","volume":"26","author":"Woodworth","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"vdag020","DOI":"10.1093\/noajnl\/vdag020","article-title":"Focused Ultrasound for Blood\u2013Brain Barrier Opening in Brain Tumor Patients: Technical Nuances","volume":"8","author":"Caldiera","year":"2026","journal-title":"Neuro-Oncol. Adv."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s43246-024-00721-y","article-title":"Device-Assisted Strategies for Drug Delivery across the Blood-Brain Barrier to Treat Glioblastoma","volume":"6","author":"Mokarram","year":"2025","journal-title":"Commun. Mater."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41698-023-00448-y","article-title":"First-in-Human Prospective Trial of Sonobiopsy in High-Grade Glioma Patients Using Neuronavigation-Guided Focused Ultrasound","volume":"7","author":"Yuan","year":"2023","journal-title":"npj Precis. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid Nanoparticles for mRNA Delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-Associated Virus as a Delivery Vector for Gene Therapy of Human Diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Rolfe, N.W., Dadario, N.B., Canoll, P., and Bruce, J.N. (2024). A Review of Therapeutic Agents Given by Convection-Enhanced Delivery for Adult Glioblastoma. Pharmaceuticals, 17.","DOI":"10.3390\/ph17080973"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"20240378","DOI":"10.1098\/rsif.2024.0378","article-title":"Effect of Infusion Direction on Convection-Enhanced Drug Delivery to Anisotropic Tissue","volume":"21","author":"Yang","year":"2024","journal-title":"J. R. Soc. Interface"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1038\/s41467-024-45818-7","article-title":"Repeated Blood\u2013Brain Barrier Opening with a Nine-Emitter Implantable Ultrasound Device in Combination with Carboplatin in Recurrent Glioblastoma: A Phase I\/II Clinical Trial","volume":"15","author":"Carpentier","year":"2024","journal-title":"Nat. Commun."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/13\/1180\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:37:10Z","timestamp":1783571830000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/13\/1180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":75,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["cells15131180"],"URL":"https:\/\/doi.org\/10.3390\/cells15131180","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]}}}